Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses

doi:10.5306/wjco.v2.i6.237

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4242)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

256

HTML

3392

Figures (1-1)

394

Tables (1-2)

200

Sum=4242

Jun 10, 2011 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Jun 10, 2011; 2(6): 237-244
Published online Jun 10, 2011. doi: 10.5306/wjco.v2.i6.237

Table 2 Overview of randomized clinical trials addressing the clinical benefit of idiotypic vaccination in patients with follicular lymphoma

Pre-treatment	Pre-vax status	Random	Endpoint	Results	Ref.
6-8 × PACE q 3w	CR	2:01	DFS	Better outcome if vaccinated	[34,35]
8 × CVP q 3w	CR, PR	2:01	PFS	No difference	[38]
4 × rituximab q 1w	CR, PR, SD	1:01	TTP	No difference	[39]

PACE: Cyclophosphamide, doxorubicin, etoposide and prednisone; q 3w: 1 cycle every 3 wk; CR: Complete response; DFS: Disease-free survival; CVP: Cyclophosphamide, vincristine, prednisone; PR: Partial response; PFS: Progression-free survival; q 1w: 1 dose weekly; SD: Stable disease; TTP: Time to progression.

Citation: Inoges S, Cerio ALD, Villanueva H, Pastor F, Soria E, Bendandi M. Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol 2011; 2(6): 237-244
URL: https://www.wjgnet.com/2218-4333/full/v2/i6/237.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i6.237